Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical (NASDAQ: ISRG) recently reported its Q3 results, with revenues lower but earnings beating our estimates.

Is Intuitive Surgical Stock A Pick After A 9% Fall In A Month Amid Mixed Q3?

Abbott Labs

Baxter

Johnson & Johnson

Medtronic

Stryker

Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad strength in their MedTech units.

The Value Deepens for Medtech Stocks: Reversal Imminent

Intuitive Surgical reported third-quarter results on Thursday after U.S. markets closed. Sales rose year over year, but contracted slightly compared to the second quarter.

Intuitive Surgical's Revenue Dipped: Is It Time to Sell?

NVIDIA

Rockwell Automation

The AI boom, exemplified by companies like OpenAI and the success of generative text models like ChatGPT, was rapid, but I see challenges ahead. The AI field is now highly competitive, and these text-based AI companies might find it hard to maintain their dazzling growth.

Invest in the Robot Takeover: 3 Stocks to Buy Before They Skyrocket

Intuitive's bariatric surgeries have slowed due to weight-loss drugs, but the company doesn't see a lasting effect.

Intuitive Surgical Sees Robot Procedures Slow. Blame Wegovy and Ozempic for Now.

Analysts at the Bank of America (BoA) remain bullish on Intuitive Surgical (NASDAQ:ISRG) on its solid procedure growth and stabilization in its bariatrics segment, reiterating their ‘Buy' rating on the stock following its third quarter financial results. Investors were not impressed by maker of robotic surgical tools' 3Q financial performance, sending the stock tumbling on Thursday.

Intuitive Surgical bariatric surgeries slowdown bottoming out amid solid procedure growth

U.S. medical device makers do not see a big impact of new weight-loss treatments on the sales of equipment used in procedures such as bariatric surgery due to the prohibitive costs of the drugs as well as reimbursement hurdles.

Medical device makers see limited hit from weight-loss drugs

Intuitive Surgical's (ISRG) third-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosted procedure sales.

Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Robust

Intuitive Surgical narrowly missed Wall Street's consensus Q3 revenue estimate. However, there's an encouraging underlying trend that many investors could be overlooking.

Why Intuitive Surgical Is a Screaming Buy on the Pullback

Intuitive Surgical, Inc. (ISRG) Q3 2023 Earnings Call Transcript

The headline numbers for Intuitive Surgical, Inc. (ISRG) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Intuitive Surgical, Inc. (ISRG) Q3 Earnings

Intuitive Surgical (NASDAQ:ISRG) shares dropped nearly 8% in extended trading Thursday after the company's quarterly revenue fell short of expectations.  The surgical robotics company posted third-quarter revenue of $1.74 billion, up from $1.56 billion a year earlier but slightly short of the analyst consensus of $1.77 billion.

Intuitive Surgical shares tumble on disappointing 3Q revenue

Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.41 per share. This compares to earnings of $1.19 per share a year ago.

Intuitive Surgical, Inc. (ISRG) Q3 Earnings Surpass Estimates

Intuitive Surgical reported better-than-expected third-quarter profit Thursday, but sales came up short and ISRG stock plummeted.

Intuitive Surgical Plummets As Robotic Surgery Giant Reports Light Third-Quarter Sales

Surgical robots maker Intuitive Surgical missed analysts' estimates for third-quarter sales on Thursday, sending its shares down nearly 8% after the bell.

Intuitive Surgical misses sales estimates, shares slump

Intuitive Surgical Inc. ISRG, -0.75% shares fell in the extended session Thursday after the surgical robotics company's quarterly revenue missed Wall Street estimates. Intuitive Surgical shares fell as much as 8% after hours, following a 0.8% rise to close the regular session at $273.45.

Intuitive Surgical's stock drops as revenue misses Street view

SUNNYVALE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended September 30, 2023.

Intuitive Announces Third Quarter Earnings

Earnings are likely to come in at about $1.42 on a per-share and adjusted basis, in line with the consensus estimate of $1.41.

Procedure Volume Growth To Drive Intuitive Surgical's Q3

Tech sector earnings season gets started after U.S. markets close on Wednesday, when Netflix and Tesla will release earnings reports.

CSX, Intuitive Surgical to Release Earnings Reports Thursday Afternoon

DexCom

Edwards Lifesciences

iShares U.S. Medical Devices ETF

Inspire Medical Systems Inc

Eli Lilly

Novo Nordisk

Insulet

ResMed

September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.

MedTech Earnings in the Age of Ozempic May Not Be That Bad

Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

Intuitive Surgical (ISRG) to Post Q3 Earnings: What's in Store?

Shopify

These two stocks have provided excellent stock market returns in the past. Both benefit from economic moats and substantial room to grow in their industries.

A Bull Market Is Coming: 2 Stocks That Could Be Worth $1 Trillion in 20 Years

Although Intuitive Surgical's valuation is significantly higher than the median for the US healthcare sector, this does not mean that it is a poor investment choice. The company is trading at a justified premium in light of the strong historical growth it has recorded and is poised to continue experiencing. ISRG is launching new products to complement its flagship da Vinci product line, pointing to continued growth.

Intuitive Surgical: When Paying A Premium Makes Sense

Alphabet

Microsoft

Tesla

Taiwan Semiconductor Manufacturing

They say we're now living in an “age of acceleration” when technological advances are coming at us at breakneck speed. Not long ago, science fiction films and novels depicted a future when we would speak to computers and they would speak back, people would take a pill each day to remain thin and private companies would shuttle astronauts and supplies into space.

7 Cutting-Edge Stocks That Could Change Humanity as We Know It

Intuitive Surgical, Inc. (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

News for Intuitive Surgical Stock (ISRG)